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Effects of a-blocker ‘add on’ treatment on blood pressure in
symptomatic BPH with or without concomitant hypertension
SH Lee, KK Park, SY Mah and BH Chung
Department of Urology, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea
We investigated the effects of ‘add on’ treatment of a-blocker (AB) on blood pressure (BP) and the
safety of ABs in men with symptomatic BPH with or without hypertension. We retrospectively
reviewed 2,924 BPH outpatients who took ABs at our institution between 2005 and 2009. BPH
symptom severity, prostate volume and BP were determined for 953 patients with their baseline
data. BP level and International Prostate Symptom Score were measured within 2 months after
AB treatment. Patients were assigned to four groups: group 1 had 272 normotensive patients on
concomitant hypertensive medication; group 2 had 293 normotensive patients not on the
medication; group 3 had 216 hypertensive patients on concomitant medication; and group 4 had
172 hypertensive patients not on the medication. The addition of AB lowered the mean systolic BP
by 16.6mmHg for group 3 and by 8.6mmHg for group 4, and diastolic BP by 18.0mmHg for group
3 (P&lt;0.05). However, normotensive groups on entry, irrespective of antihypertensive medication,
showed no significant BP changes from baseline after AB medication. In the hypertensive groups
on entry, the doxazosin gastrointestinal therapeutic system (GITS) resulted in significant
reductions in systolic BP from 142.2 to 134.9mmHg and in diastolic BP from 97.6 to 84.6mmHg.
When analyzed by AB regimen, the incidence of BP-related adverse events was comparable. AB
therapy for BPH can have an appropriate and beneficial effect on BP, especially in baseline
hypertensive patients. Doxazosin GITS treatment resulted in optimal management of BP within the
normal range, especially in pharmacologically or physiologically hypertensive patients.
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Introduction
BPH is often encountered in aging men, and it is the
most common urological disorder.1 The prevalence of
BPH and hypertension increases with age, hence both are
common diseases in elderly males.2 An estimated 25% of
men aged 460 years have concomitant BPH and
hypertension.2 Although BPH and hypertension seem
to involve separate disease processes, it has been
postulated that age-related increases in sympathetic tone
may have a role in their pathophysiologies.2,3
Treatments for BPH include surgical or medical
therapy. The number of patients treated for BPH is
rapidly increasing in Korea, and noninvasive medical
therapy is being increasingly chosen as the primary
treatment option.4 Of the medications for BPH, selective
a1-adrenoceptor antagonists have been considered as an
effective, noninvasive treatment option for men with BPH.
However, the administration of a-blockers (ABs) to patients
with BPH raises the concern that patients who are taking
other antihypertensive drugs and those with a normal
blood pressure (BP) level could experience excessive
reductions in BP that would cause hypotensive symptoms.
One agent that is shown to provide rapid relief is
doxazosin, a selective a1-adrenoceptor antagonist that is
also used to treat hypertension. Doxazosin has been shown
to be effective and well tolerated in the treatment of
symptomatic BPH in hypertensive patients.5 However, a
previous placebo-controlled study of doxazosin in normo-
tensive BPH patients showed a decrease in BP compared
withplacebo.6 Although other ABs, such as tamsulosin and
alfuzosin, are effective for treating patients with BPH and
as part of combined therapy in patients with hyperten-
sion,7,8 there are few reports comparing their effects on BP
in BPH patients depending on antihypertensive medica-
tion. Therefore, we aimed to retrospectively evaluate the
effects of ABs on BP in BPH patients with or without
concomitant hypertension. We also evaluated the efficacy
and safety of ABs in these patients.
Methods
Study design
We retrospectively reviewed 2924 BPH patients who had
been initially diagnosed with BPH and prescribed with
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a1-adrenoceptor antagonists at our institution between
January 2005 and October 2009. The symptoms of BPH
were recorded through a routine initial evaluation of
BPH using a transrectal ultrasound of the prostate,
uroflowmetry, International Prostate Symptom Score
(IPSS), urine analysis and PSA determinations. At the
initial visit, BP level and concomitant hypertension-
related medication were also recorded. BP and IPSS were
measured within 2 months after AB treatment. Hyper-
tension was defined as a diastolic BP of 90mmHg or
above in a sitting position. Adverse events (AEs) were
defined as symptoms that require discontinuation or
change of the current AB medication.
Patients
Patients were excluded from this study if they had ever
taken medications such as AB or 5-a-reductase inhibi-
tors. Patients were also excluded if they had neurogenic
bladder dysfunction, confirmed prostate cancer, acute
or chronic urinary retention status, acute or chronic
prostatitis within the last 3 months, serum PSA levels
over 10 ngml1, a history of recurrent urinary tract
infection or bladder stones and previous TURP or other
surgical intervention related to BPH. We also excluded
patients who were taking other antihypertensive drugs
at the baseline point and until follow-up BP measure-
ments. Of the 2924 patients enrolled, BPH symptom
severity (assessed by IPSS and urinary flow rate),
prostate volume, baseline BP (before AB medication)
and follow-up BP (after AB medication) measurements
were determined for 953 patients using baseline data.
Patients were assigned to four groups: group 1 had 272
normotensive patients on concomitant hypertensive
medication; group 2 had 293 normotensive patients not
on the medication; group 3 had 216 hypertensive patients
on concomitant medication; and group 4 had 172
hypertensive patients not on the medication.
Statistical analysis
All analyses were conducted with SAS statistical soft-
ware, version 9.1 (SAS Institute, Cary, NC, USA). The
means of the groups were compared using Student’s
t-test and/or analysis of variance test. After performing a
covariate analysis of variance adjusting for age and
prostate volume, the significance of differences in BP
among groups, based on baseline BP and AB regimen,
was examined using two-way analysis of covariance
with subsequent linear contrasts (Table 1). The w2-test
was used to determine the statistical significance of
differences in AEs among groups according to AB
regimen. Differences were considered statistically
significant when the probability of error was less than
5% (Po0.05).
Results
Of 953 patients enrolled, 385 patients (40.4%) took
tamsulosin 0.2mg; 203 (21.3%) took alfuzosin 10mg;
197 (20.7%) were on the doxazosin gastrointestinal
therapeutic system (GITS) 4mg; and 168 (17.7%) took
terazosin 2mg once daily. The overall mean age was
63.2±5.8 years and the mean prostate volume
was 38.1±5.5 cc. The mean duration of follow-up was
58.8±7.3 days, and there was no significant difference in
the duration of follow-up by AB regimen.
The addition of ABs lowered the mean systolic BP by
16.6mmHg for group 3 and by 8.6mmHg for group 4,
and diastolic BP by 18.0mmHg for group 3 (Po0.05)
(Figure 1). However, normotensive groups on entry,
irrespective of antihypertensive medication, showed no
significant BP changes from baseline values after AB
medication. After adjusting for age, significant changes
in mean systolic BP from baseline values were found in
group 2 (D0.4mmHg) versus group 3 (D16.6mmHg);
changes in diastolic BP were found in group 1
(Dþ 1.6mmHg) versus group 3(D18.0mmHg), group
1(Dþ 1.6mmHg) versus group 4 (D8.2mmHg), group
2 (Dþ 1.7mmHg) versus group 3 (D18.0mmHg) and
in group 2 (Dþ 1.7mmHg) versus group 4
(D8.2mmHg) (Figure 1).
Baseline and follow-up BP levels according to AB
regimen are shown in Table 2. Follow-up systolic BP was
only significantly lower in the doxazosin GITS treatment
group. There were significant improvements in IPSS total
score from baseline data for all drugs. However, there
were no significant differences among drugs. Figure 2
shows the mean change from baseline data in BP for
hypertensive and normotensive patients according to AB
regimen. Of the 197 patients in the doxazosin GITS
group, 91 patients had baseline high BP (53 with
Table 1 The baseline characteristics of patients according to blood pressure
Normotension Hypertension
Group 1 Group 2 Group 3 Group 4
No 272 293 216 172
Age 62.8±5.7 63.3±4.4 64.2±5.8 65.9±6.1
Systolic BP (mmHg) 124.8±2.1 125.3±2.6 140.4±1.9 139.8±2.4
Diastolic BP (mmHg) 74.5±0.9 76.2±1.0 93.1±1.2 94.4±1.3
IPSS (total) 14.7±0.5 15.6±0.5 14.8±0.3 14.2±0.4
QOL 3.5±0.2 3.6±0.5 3.7±0.4 3.0±0.5
Prostate volume (cc) 38.8±6.1 32.2±4.5 41.3±7.1 37.3±5.8
PSA (ngml1) 2.1±0.2 1.6±0.3 1.7±0.5 2.0±0.6
Qmax (ml s1) 11.0±1.7 10.7±0.5 11.6±0.8 10.7±1.3
Residual urine volume (cc) 58.6±10.2 43.6±7.1 62.9±8.4 55.4±6.6
Abbreviations: BP, blood pressure; IPSS, international prostate symptom score; Qmax, urinary flow rate; QOL, quality of life.
The values for age, blood pressure, prostate volume, PSA, IPSS, QOL, Qmax, and residual urine volume are means±s.d.
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Figure 1 Comparison of the mean changes in blood pressure (BP) from baseline values according to group.
Table 2 The baseline and clinical characteristics of patients according to a-blocker regimen
Tamsulosin 0.2mg Alfuzosin 10mg Doxazosin GITS 4mg Terazosin 2mg
No 385 203 197 168
Age 62.5±7.0 61.8±8.2 66.1±6.0 64.3±7.6
IPSS (total)
Baseline 16.0±2.1* 15.5±2.6* 16.5±1.9* 15.8±2.4*
Follow up 11.6±2.0* 10.6±1.8* 12.0±1.3* 10.6±1.5*
QOL
Baseline 3.7±0.2* 3.9±0.5* 4.0±0.4* 3.9±0.5
Follow up 3.0±0.3* 3.1±0.7* 3.3±0.6* 3.4±0.3
Prostate volume (cc) 35.8±6.1 32.2±4.5 41.3±7.1 38.3±5.8
PSA (ngml1) 2.5±0.2 1.9±0.3 2.4±0.5 1.7±0.6
Qmax (ml s1) 11.0±1.7 11.7±0.5 10.6±0.8 10.0±1.3
Residual urine volume (cc) 60.6±10.2 51.6±7.1 67.9±8.4 62.4±6.6
Baseline BP (mmHg)
Systolic 129.4±6.8 130.1±9.3 131.3±8.3* 129.8±7.9
Diastolic 83.6±9.2 84.5±5.9 84.9±6.7 85.8±6.2
BP following ‘add on’ treatment
Systolic 127.6±7.2 126.8±10.6 125.1±10.9* 126.2±9.1
Diastolic 83.3±9.4 84.2±8.0 83.5±6.9 84.1±7.8
Adverse events following ‘add on’ treatment
Dizziness, N(%) 11 (2.2) 7 (3.4) 10 (5.1) 8 (4.8)
Postural hypotension, N(%) 7 (1.9) 5 (2.5) 11 (5.6) 7 (4.2)
Etc., N(%) 3 (0.8) 2 (1.0) 2 (1.0) 5 (3.0)
Abbreviations: BP, blood pressure; GITS, gastrointestinal therapeutic system; IPSS, international prostate symptom score; Qmax, urinary flow rate; QOL, quality of life.
The values for age, blood pressure, prostate volume, PSA, IPSS, QOL, Qmax, and residual urine volume are means ±s.d.
*Po0.05 by ANCOVA test.
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concurrent antihypertensive medication versus 38 with-
out antihypertensive medication). In baseline hyperten-
sive BP patients, treatment with doxazosin GITS resulted
in significant reductions in systolic BP from 142.2mmHg
to 134.9mmHg and in diastolic BP from 97.6mmHg to
84.6mmHg (D–7.3 and D–13.0mmHg, respectively).
The incidence of BP-related side effects, such as
dizziness or postural hypotension, was significantly
higher in group 3 (P¼ 0.021). When analyzed by AB
regimen, the incidence of BP-related side effects was
comparable, and the differences among groups were not
significant (Table 2).
Discussion
Because BPH and hypertension are chronic conditions,
long-term medication must be safe and continuously
effective during treatment. The efficacy of ABs for BPH
treatment has been well documented, and our results
compare favorably with those of previous studie-
s.4,9,10However, despite similar efficacy, ABs have differ-
ent AEs, and many AEs are secondary to reduction in BP
(for example, dizziness and orthostatic hypotension).9 In
a recent meta-analysis,11 alfuzosin, terazosin and dox-
azosin showed a significantly higher risk of developing
vascular events compared with placebo, and tamsulosin
showed an increase with no significance. Our previously
reported treatment with doxazosin GITS for 1 year
resulted in a significantly higher reduction in BP in
hypertensive patients than in normotensive patients.12
Furthermore, BP in the concomitant antihypertensive
medication group was reduced significantly compared
with that in the no-medication group. However, in the
present study, treatment with doxazosin GITS resulted in
significant reductions in systolic and diastolic BP,
especially in baseline hypertensive BP patients, irrespec-
tive of concomitant antihypertensive medication. These
contradictory findings might result from the relatively
small number of patients in the concomitant antihyper-
tensive medication group (n¼ 18) in the previous study.
Our results suggest that doxazosin GITS treatment has
the ‘additional benefit’ of lowering BP in pharmacologi-
cally or physiologically hypertensive patients. However,
we were unable to find out why the AB ‘add on’
treatment lowered BP, especially in patients with base-
line high BP. Our results warrant future prospective
studies to elucidate the underlying mechanism.
In this study, the overall incidence of AEs was
comparable among the four groups, even though systolic
BP was significantly lower in the doxazosin GITS group
after doxazosin GITS ‘add on’ treatment (Table 2).
Because ABs cause vasodilation, vascular AEs take the
form of dizziness, presyncope or syncope. These symp-
toms can be life threatening, particularly in an older
patient population. Terazosin and doxazosin, originally
developed as antihypertensive drugs, are nonsubtype
selective ABs, and both are associated with a larger
number of vasodilatory side effects than either tamsulo-
sin or alfuzosin.13–16In this study, the occurrence of
medication-related AEs was lower than the 16.1%
previously reported by Kirby et al.17, possibly because
the present study had a short-term follow-up period.
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Figure 2 The mean s.d. change in blood pressure (BP) from baseline values for hypertensive and normotensive patients according to
a blocker regimen. DBP, diastolic BP; SBP, systolic BP.
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There are several limitations. First, it is a retrospective
study with a short-term follow-up period. A prospective
study with a long-term follow-up period is needed to
confirm our findings. Another limitation was that the
safety aspect of our study was limited to vascular AEs
because of their potentially life-threatening effects. We
only identified with certainty those of sufficient severity
to require discontinuation of ABs. Finally, we measured
BP only with the patient in the seated position. We
acknowledge this methodological flaw of not measuring
BP in a supine position, in addition to the sitting
position, to rule out any orthostatic hypotension that
might be present. However, despite these limitations, our
results provide adequate preliminary data to support a
prospective, randomized, controlled trial of the effect of
AB ‘add on’ treatment on BP in patients with base-
linehigh or normal BP.
Conclusions
AB therapy for BPH can have an appropriate and
beneficial effect on BP, especially in baseline hyperten-
sive patients. Furthermore, doxazosin GITS treatment
resulted in optimal management of BP within the normal
range, especially in pharmacologically or physiologically
hypertensive patients.
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